Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments. The strategy could also help stop the spread of HIV...
A twice-yearly injection of Lenacapavir offers a 96% reduced risk of infection overall, making the injection significantly more effective than the daily oral PrEP...
Overall peer support and providing access to gender-affirming hormone therapy (GAHT) and other needed services likely lead to an increase in HIV pre-exposure prophylaxis...
With the injectable antiretroviral drug lenacapavir found to be “safe and 100% effective as long-acting HIV pre-exposure prophylaxis (PrEP) among cisgender women in a...
Even a modest increase in patient out-of-pocket costs for PrEP could result in a sharp increase in prescription abandonment—and a subsequent large increase in...